Can a new IV antiviral tame two stubborn viruses?

NCT ID NCT04706923

Completed Disease control Sponsor: SymBio Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called brincidofovir, given intravenously, in people aged 2 months and older who have an adenovirus or cytomegalovirus infection. The study aims to see how safe and tolerable different doses are, and whether the drug can reduce the amount of virus in the blood. Participants receive the drug twice weekly or once weekly for four weeks, with close monitoring for side effects and antiviral activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brincidofovir (BCV), an experimental antiviral drug given intravenously
What this could lead to: If successful, this could lead to a new treatment option for serious adenovirus or cytomegalovirus infections, especially in people with weakened immune systems.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness. Possible side effects and safety concerns are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOVIRUS INFECTIONS CYTOMEGALOVIRUS INFECTION

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Research Site

Los Angeles, California, 90027, United States
Research Site

Los Angeles, California, 90095, United States
Research Site

San Francisco, California, 94158, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Seattle, Washington, 98109, United States
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.